Benefits

Joint Health

Supports symptoms of mild to moderate osteoarthritis*
‍
Supports joint function*
‍
Supports joint stiffness*
‍
Supports joint comfort*
‍

Levagen^® demonstrated dose-dependent improvement (300mg & 600mg) in WOMAC scores* (discomfort, stiffness and function) compared to the placebo in the management of mild to moderate osteoarthritis (Steels et al. 2019).

‍

Levagen^®+ offers morning and evening joint ache reduction when compared to placebo over a 14 day period, suggesting that PEA may be a beneficial and effective treatment for joint pain.* (Briskey, et al. 2021)

‍

In one of its most recent published clinical studies, a highly absorpable liposomal form of Levagen+, PlexoZome Levagen+ displayed significantly more knee discomfort events resolved at 60 minutes and 75 minutes and reduced discomfort at 60 minutes, equivalent to a 55% reduction relative to baseline. (Deb, et al. 2025)

Sleep

Levagen^®+ was shown to reduce anxiety* and improve QOL* (Rao et al. 2021), providing PEA's relevance and application in sleep.

PEA is part of the extended endocannabinoid family, thus may promote restful sleep through indirect activation of the calm-inducing CB1 receptors (Costa et al. 2008). It can also increase restful REM sleep by activating TRPV1 channels* (Petrosino et al. 2015).

Sports Performance & Recovery

Human clinical study by (Mallard et al. 2020) demonstrates the benefits of Levagen^®+ for:

Recovery: Significantly reduces levels of myoglobin* (a marker for muscle damage) and stimulates the Akt/PkB pathway* (downstream region of the mTOR pathway involved in muscle protein synthesis).

‍Performance: Significantly reduces lactate levels, allowing to exercise at higher intensities and/or for a longer duration*.

Please fill out a contact form to request access to our Sports Nutrition White Paper.

Cognitive Health

Levagen^®+ efficacy was studied at 700mg or a matching placebo for 6 weeks in a double armed, cross-over trail.

Levagen^®+ supported significant improvement in serum BDNF levels when compared to placebo* and helped to improve memory through better first success and fewer errors*. (Kim, et al. 2024)

In one of its most recent studies, Levagen^®+ was evaluated for its effect on stress in females. Results indicated that Levagen^®+ significantly increased Standard Deviation of Normal-to-Normal in women* and supports enhanced physiological stress regulation*. (Deb, et al. 2025)

Discomfort

Levagen^®+ was proven to reduce diabetic peripheral neuropathic discomfort* over an 8 week period.

PEA offers a variety of benefits and has been studied as an alternative to common relievers*. Levagen^®+ resolved significant head discomfort* and symptoms* faster than a traditional options, without accentuating side effects. (Briskey, et al. 2022)

In a follow-up head discomfort study, Levagen^®+ was shown to significantly reduce and resolve head discomfort*. (Briskey, et al. 2024)

‍
In its newest study, Levagen+ was shown to significantly reduce menstrual discomfort at just 2 hours post initial dose, with further significance seen at 2.5 hours after the second dose. (Rao, et al. 2025)

Skin Health

Levagen^®+ was shown to significantly reduce skin dryness and redness, and reduced a total POEM score in a topical formulation applied twice daily for 4 weeks. (Rao, et al. 2024)

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This material is educational in nature and is not intended to serve as regulatory and/or legal advice.

Not all claims made are valid in all global regions.

Saanroo

Home